VRX - Valeant Pharmaceuticals Intern
This page shows which of the focused investors we track hold VRX and how their positions changed, so you can see how much conviction the group has in the stock.
In Q4 2013 it was held by 9 managers with an aggregate reported value of $9.38B, which is 1.33% of the combined portfolio.
As of Q4 2013, 9 tracked institutional managers held VRX (Valeant Pharmaceuticals Intern) with an aggregate reported value of $9.38B — 1.33% of the combined AlphaBaseline portfolio.
Get email alerts when a tracked manager trades VRX — sign in or create a free account.
- Source
- Curated SEC 13F filings
- Period
- Q4 2013
- Ticker
- VRX
13F data is delayed and excludes shorts/non-13F assets.
Holders
| 1 | Ruane Cunniff LP - Ruane Cunniff LP | 22.40% | Reduce -1.0% | 34,305,656 | $4.03B |
| 2 | ValueAct Capital - ValueAct Capital | 18.37% | - | 18,923,877 | $2.22B |
| 3 | Viking Global Investors - Viking Global Investors | 4.56% | Reduce -6.9% | 8,329,004 | $977.83M |
| 4 | Stephen Mandel - Lone Pine Capital | 4.17% | Reduce -0.3% | 7,756,485 | $910.61M |
| 5 | Glenn Greenberg - Brave Warrior Advisors | 29.38% | Reduce -7.0% | 6,113,227 | $717.69M |
| 6 | Wallace Weitz - Weitz Investment Management | 7.27% | Reduce -9.5% | 1,849,200 | $217.1M |
| 7 | Lee Ainslie - Maverick Capital | 2.48% | New | 1,633,838 | $191.81M |
| 8 | First Eagle - First Eagle Investment Management | 0.29% | - | 902,742 | $105.98M |
| 9 | Christopher Davis - Davis Advisors | 0.03% | Reduce -15.6% | 97,534 | $11.45M |
Loading holder history for VRX…